Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Subscribe To Our Newsletter & Stay Updated
